BLSM · BlossomHill Therapeutics, Inc. · Webcasts, Transcripts & Audio

The latest filing states the doubt was alleviated.

“there are conditions and events, considered in the aggregate, that raise substantial doubt about the Company's ability to continue as a going concern within one year from the date that these financial statements are issued. The Company has incurred net losses and negative cash flows from operations since inception, has a significant accumulated deficit and expects to continue to incur net losses for the foreseeable future. The Company has never generated any revenue from product sales and does not expect to generate any revenues from product sales unless and until it successfully completes development of and obtains regulatory approval for its product candidates, which will not be for several years, if ever. The Company has an accumulated deficit of $179.8 million as of June 30, 2026. During the six months ended June 30, 2026, the Company used $44.2 million of cash for operating activities. As of June 30, 2026, the Company had $95.4 million in cash and cash equivalents. In August 2026, the Company closed on its Initial Public Offering (the "IPO"), in which the Company received aggregate net proceeds of $151.7 million, inclusive of the partial exercise of the underwriters' option to purchase additional shares (the "IPO Proceeds"). Management believes that the Company's existing cash resources, together with the IPO Proceeds, will be sufficient to fund operations for at least 12 months following the issuance of these unaudited condensed financial statements.”